Exchange: NASDAQ·Updated 04:28 PM EST

PLSE News

News
all
press releases
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity...
Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity...
Business Wire
More News
ISRG, STE and PLSE offer exposure to AI-enabled medical devices, rising healthcare demand and potential price upside, making them stocks to watch in 2026.
Zacks
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced plans to participate in the upcoming Piper Sandler 38th Annual Healthcare Conference in New York, NY. Pulse...
Business Wire
Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced interim six-month results from PRECISE-BTN, a prospective, multicenter U.S. study evaluating the nPulse Vybrance...
Business Wire
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +8.57% and -21.00%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2026. Pulse Biosciences delivered...
Business Wire
Si-Bone (SIBN) delivered earnings and revenue surprises of +38.46% and +0.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
DexCom (DXCM) delivered earnings and revenue surprises of +10.61% and +1.64%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced plans to participate in the upcoming Stifel 2026 Healthcare Conference in New York, NY. Pulse Biosciences...
Business Wire

Advertisement|Remove ads.